Passage Bio to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

Rhea-AI Summary

Passage Bio (NASDAQ: PASG), a clinical-stage genetic medicines company, announced that CFO Simona King will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference from June 13-16, 2022. The event, scheduled for June 16 at 8:40 a.m. PT (11:40 a.m. ET), will be webcast live on the company’s website. Passage Bio focuses on developing transformative therapies for central nervous system disorders and is advancing clinical programs for conditions like GM1 gangliosidosis and Krabbe disease.

PHILADELPHIA, June 09, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that Simona King, chief financial officer of Passage Bio, will participate in a fireside chat at the upcoming Goldman Sachs 43rd Annual Global Healthcare Conference being held from June 13-16, 2022 in Rancho Palos Verdes, CA.

Format: Fireside Chat
Date: Thursday, June 16, 2022
Time: 8:40 a.m. PT (11:40 a.m. ET)

A live webcast of the event will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the presentation will be available for 30 days following the events.

About Passage Bio
Passage Bio (Nasdaq: PASG) is a clinical-stage genetic medicines company on a mission to provide life-transforming therapies for patients with CNS diseases with limited or no approved treatment options. Our portfolio spans pediatric and adult CNS indications, and we are currently advancing three clinical programs in GM1 gangliosidosis, Krabbe disease and frontotemporal dementia with several additional programs in preclinical development. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania’s Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. Through this collaboration, we have enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies. More information is available at www.passagebio.com.

For further information, please contact:

Investors:
Stuart Henderson
Passage Bio
267.866.0114
shenderson@passagebio.com

Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312.961.2502
MikeBeyer@sambrown.com 

FAQ

What is the date and time of Passage Bio's participation in the Goldman Sachs Global Healthcare Conference?

Passage Bio will participate on June 16, 2022, at 8:40 a.m. PT (11:40 a.m. ET).

Where can I watch the live webcast of Passage Bio's fireside chat?

The live webcast will be available on Passage Bio’s Investors & Media section of their website.

What are the main focuses of Passage Bio's clinical programs?

Passage Bio focuses on therapies for central nervous system disorders, including GM1 gangliosidosis and Krabbe disease.

Who is presenting at the Goldman Sachs Global Healthcare Conference for Passage Bio?

CFO Simona King will represent Passage Bio during the conference.

How long will the replay of the Passage Bio presentation be available?

The replay will be available for 30 days following the event.